Figure 4.
Schematic representation of the mechanism of action of synthetic corticosteroids (CS), mycophenolate mofetil, cyclophosphamide, inebilizumab, rituximab, belimumab, abatacept, nintedanib, tocilizumab, tofacitinib, fresolimumab, metelimumab, and pirfenidone in reducing fibrosis in SSc. Abbreviations: ECM = extracellular matrix; TGF-β = transforming growth factor-β.